My Prostate Cancer Stopped Responding to Hormone Therapy — What Are My Options Before Chemotherapy?

When Hormone Therapy Stops Working

Hormone therapy — also called androgen deprivation therapy, or ADT — is usually one of the first treatments for prostate cancer that has spread. It works by lowering testosterone, the hormone that helps prostate cancer cells grow. For many men, it controls the cancer for months or even years.

But over time, many cancers adapt and start growing again, even when testosterone levels stay low. When that happens, doctors call it metastatic castration-resistant prostate cancer — or mCRPC.

Getting this news can feel overwhelming. You may be wondering: "Is chemotherapy the only path forward?" For most men, the answer is no. Several treatment options are available before chemotherapy is needed. This article walks through them in plain language.

What Does "Castration-Resistant" Actually Mean?

The word "castration-resistant" does not mean the cancer is untreatable. It simply means the cancer has learned to grow without relying on testosterone the way it used to.

Your care team may suspect this is happening if your PSA level starts to rise while you are still on ADT, or if imaging scans show new or growing areas of cancer. Your care team may begin to suspect resistance to hormone therapy if your PSA level begins to rise on continued treatment.

If the cancer has also spread to the bones — which is common at this stage — your doctors will factor that into which options are right for you.

Why the Window Before Chemotherapy Matters

Chemotherapy can be effective for prostate cancer and remains an important tool. But it carries a heavier side-effect burden. Many men and their doctors prefer to try other options first — ones that may delay the need for chemotherapy while still controlling the cancer.

Research supports that this window is real and worth using. The American Society of Clinical Oncology (ASCO) recommends continuing androgen-deprivation therapy indefinitely in patients with mCRPC, while adding other therapies based on each person's situation.

Here are the main treatment options that may be available to you before chemotherapy:

Option 1: Next-Generation Hormone Therapies (ARPIs)

If your cancer progressed on one hormone therapy, your doctor may consider a more powerful hormone-blocking drug. These are called androgen receptor pathway inhibitors, or ARPIs.

These drugs block the androgen receptor — the switch that cancer cells use to respond to testosterone signals, even when testosterone is low. In clinical trials, first-line treatment for asymptomatic or mildly symptomatic mCRPC has generally involved novel hormonal agents such as abiraterone or enzalutamide.

These drugs work best if you have not already received one. Response rates to a second ARPI are low, and chemotherapy is often considered the next step for patients who have already progressed on one ARPI. Your oncologist will weigh whether switching to a different ARPI makes sense in your case.

Option 2: Lu-177 PSMA Therapy — Now Approved Before Chemotherapy

One of the biggest recent advances in prostate cancer care is the approval of Lu-177 PSMA therapy earlier in the disease course — before chemotherapy is needed.

Lu-177 PSMA is a radioligand therapy. It uses a targeting molecule that seeks out a protein called PSMA (prostate-specific membrane antigen), found on the surface of most prostate cancer cells. Once attached, it delivers a small, precise dose of radiation directly to the cancer cell. You can read a full explanation in our guide: What Is Lu-177 Therapy? A Patient-Friendly Guide to How It Works.

The key clinical trial is called PSMAfore. It enrolled men with mCRPC who had become resistant to one ARPI and had not yet had chemotherapy. On March 28, 2025, the FDA approved Lu-177 PSMA in the chemotherapy-naive mCRPC setting, based on the results of the phase 3 PSMAfore trial. Lu-177 PSMA therapy can now be used before chemotherapy for eligible patients.

The PSMAfore trial found that using Lu-177 PSMA before chemotherapy showed clinical benefit in radiographic progression-free survival and spared patients from the more difficult side effects of chemotherapy.

There is also a biological case for using Lu-177 PSMA earlier. Research suggests that earlier use may allow for more effective dosing with potentially reduced toxicity, particularly before cumulative bone marrow compromise occurs.

To qualify, your cancer cells need to show adequate PSMA expression on a PSMA PET scan. Not everyone qualifies. For eligibility details, see: Am I a Candidate for Lu-177 PSMA Therapy? A Plain-Language Guide to Eligibility. To learn what treatment day looks like, read: What Happens During a Lu-177 PSMA Infusion? A Step-by-Step Guide for First-Time Patients.

For patients in India or those exploring international treatment options, access to Lu-177 PSMA therapy has grown considerably. See our overview: Why India Is Becoming the World's Destination for Lutetium Therapy.

Option 3: Radium-223 for Bone-Only Metastases

If your cancer has spread mainly or entirely to your bones — and not to organs like the liver or lungs — Radium-223 may be worth discussing with your care team.

Radium-223 is a different kind of radiopharmaceutical. Rather than targeting a protein on cancer cells, it behaves like calcium and is taken up by areas of active bone turnover — exactly where bone metastases tend to grow. Once there, it emits short-range alpha radiation that damages cancer cells in the bone.

The FDA approved Radium-223 for mCRPC patients whose metastases are limited to the bones. In the pivotal ALSYMPCA trial, Radium-223 significantly improved median overall survival compared with placebo — 14.0 months versus 11.2 months.

For men who have received, are ineligible for, or want to avoid chemotherapy, Radium-223 may be a viable treatment option. It has also been shown to reduce bone pain and delay skeletal complications, which can strongly affect quality of life at this stage.

One key limitation: Radium-223 is not appropriate for men with visceral metastases (spread to organs other than bone). It should not be used in patients with visceral metastases or bulky nodal disease. Your care team will use imaging to determine whether you fit the profile.

ASCO guidelines also recommend Radium-223 for patients with symptomatic bone-only disease.

Option 4: PARP Inhibitors (for Men With Certain Gene Mutations)

Some men with mCRPC carry mutations in DNA repair genes — most commonly BRCA1 or BRCA2. If you have one of these mutations, PARP inhibitors may be a meaningful option before or instead of chemotherapy.

PARP inhibitors block a protein that cancer cells use to repair their own DNA damage. In cells that already have a DNA repair mutation, blocking PARP can cause enough DNA damage to kill the cancer cell.

PARP inhibitor therapies improve outcomes mainly in HRR- and BRCA-mutated mCRPC, and molecular selection is key to getting the most benefit while limiting toxicity.

This is why genetic testing — from both tumor tissue and a blood sample — is strongly encouraged at this stage. ASCO guidelines recommend early adoption of somatic genetic testing in men with mCRPC. If you have not had this testing yet, ask your oncologist. The results can open — or rule out — specific treatment paths.

If your genetic testing shows a BRCA mutation, ASCO recommends PARP inhibitor monotherapy for patients with BRCA1/2 alterations who have received a prior ARPI.

Option 5: Immunotherapy (for Select Patients)

Immunotherapy plays a more limited role in prostate cancer than in some other cancers. For a small group of men whose tumors have specific features — such as microsatellite instability (MSI-high) or mismatch repair deficiency — certain immunotherapy approaches may apply.

Immunotherapy has shown limited benefit in unselected patients with mCRPC, and new strategies need to be explored. This is another reason biomarker and genetic testing matters: it helps your care team identify whether you are among the patients who may benefit.

There is also a cellular immunotherapy called sipuleucel-T, which is most often prescribed for cancer that has become resistant to androgen deprivation therapy and may be used before or after chemotherapy. Its use is more common in the United States, and your oncologist can advise whether it fits your situation.

What About Bone-Protective Treatments?

Bone metastases can cause serious problems over time, including pain, fractures, and spinal cord compression. Even while pursuing a treatment that targets the cancer itself, your care team may recommend a bone-protective agent.

ASCO guidelines state that patients with mCRPC and bony metastases should receive a bone-protective agent. These drugs do not fight the cancer directly, but they can help prevent or delay bone complications — which matters for quality of life and your ability to stay on cancer treatment.

How Do You and Your Doctor Choose?

No two patients with mCRPC are the same. The treatment your care team recommends will depend on several factors:

• What treatments you have already had — Prior ARPI use affects whether Lu-177 PSMA or a different ARPI is the right next step.
• Where the cancer has spread — Bone-only disease opens the door to Radium-223. Spread to organs may close it.
• Your PSMA PET scan results — Adequate PSMA expression is required for Lu-177 PSMA therapy.
• Your genetic test results — BRCA1/2 or other DNA repair mutations may make PARP inhibitors a strong option.
• Your symptoms and overall health — Your ability to tolerate certain treatments matters.
• Your personal goals — Quality of life, treatment schedule, and what matters most to you should be part of the conversation.

The treatment landscape for mCRPC is changing quickly, and decisions at this stage are genuinely complex. A second opinion from a specialist in advanced prostate cancer — including a nuclear medicine physician if Lu-177 PSMA or Radium-223 is being considered — can be very valuable.

A Note on Clinical Trials

Several clinical trials are studying new ways to use Lu-177 PSMA and other radioligand therapies earlier in the disease course, in combination with other treatments, and in newly diagnosed patients. Ongoing trials such as PSMAaddition, SPLASH, ECLIPSE, ARROW, and LUNAR are studying earlier treatment settings for prostate cancer.

If you are interested in clinical trials, ask your oncologist whether you may be eligible. Participating can sometimes provide access to newer treatments while contributing to research that helps future patients.

When to Talk to Your Doctor

If your PSA is rising while you are on hormone therapy, if imaging shows new areas of cancer, or if you are having new bone pain or other symptoms, talk to your oncologist promptly. Bring a list of your current medications and prior treatments. Ask about genetic and biomarker testing if you have not had it. Ask whether a referral to a specialist in radioligand therapy or advanced prostate cancer makes sense for your situation.

There are more options than ever before for men at this stage, and you do not have to face it alone.

---

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.